CD8A and metabolic dysfunction-associated steatohepatitis: More recently, ICI treatment has been less effective for NASH‐related HCC because CD8+ positive lymphocytes in NASH‐associated HCC have a reduced immune response to cancer antigens due to reduced antitumor surveillance.8